68 results about "Acetyltransferase" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

The invention relates to the field of genetic engineering and fermentation engineering, and discloses a genetically engineered bacterium for producing melatonin and application of the genetically engineered bacterium in fermentation production of melatonin. According to the invention, genes of mtrA, PTPS, SPR, PCD and DHPR of related enzymes synthesized by coding 2-amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4 (1H)-pterin diketone and genes of L-2-amino-3 (beta-indole) propionic acid monooxygenase, oxymethyltransferase, N-acetyltransferase and decarboxylase are co-expressed on the genetically engineered bacterium, so that the gene engineering bacterium is obtained. The strain can be used for fermentation production of melatonin, and experiments show that the yield of the strain can reach 6480 mg / L.

The invention discloses genetically engineered corynebacterium glutamicum and an application of the genetically engineered corynebacterium glutamicum in preparation of ectoine, and the genetically engineered corynebacterium glutamicum contains an L-diaminobutyric acid transaminase gene ectB, an L-diaminobutyric acid acetyltransferase gene ectA and an ectoine synthetase gene ectC, the invention relates to an aspartic acid transferase gene aspB, an aspartic acid kinase gene lysC and an aspartic acid semialdehyde dehydrogenase gene asd, wherein the nucleotide sequences of the gene aspB, the gene lysC and the gene asd are respectively as shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention further discloses a preparation method of the aspartic acid transferase gene aspB, the aspartic acid kinase gene lysC and the aspartic acid semialdehyde dehydrogenase gene asd. After the recombinant corynebacterium glutamicum constructed by the invention is fermented for 60 hours, the yield of ectoine can reach 50g / L. The genetically engineered corynebacterium glutamicum disclosed by the invention has important practical significance on industrial production and large-scale application of ectoine.

The invention belongs to the technical field of biological medicine, and particularly relates to a biomarker related to acetylation of a K147 site of histone H1 and application of the biomarker in liver cancer treatment. The invention relates to a biomarker related to acetylation of a K147 site of histone H1. According to the biomarker, the histone H1 is subjected to acetylation modification at the K147 site. Bioinformatics analysis shows that the high expression state of acetyltransferase ELP3 is closely related to the occurrence and development of hepatocellular carcinoma, ELP3 can directly regulate and control acetylation modification of histone H1, then the core catalytic site of ELP3 is verified through site mutation, and the K147 acetylation site located on the histone H1 is precisely determined. Test results show that intervention of the ELP3-H1-K147 pathway can significantly inhibit proliferation and migration ability of liver cancer cells, and can provide research and development direction and theoretical support for development of novel liver cancer treatment drugs.

The present invention relates to an antisense oligonucleotide (oligomer) complementary to NAT8L (N-acetyltransferase 8-like) precursor mRNA, which is capable of inhibiting the expression of NAT8L in a cell that expresses NAT8L. Inhibition of the expression of NAT8L is beneficial to the treatment of Canadian disease (Canadian disease).

This invention provides an engineered bacterium for producing ectoine, its preparation method, and its application. The engineered bacterium is prepared using a method comprising the following steps: using *Corynebacterium glutamicum* as the starting strain, feedback inhibition by aspartate kinase LysC is relieved, the activity of the gene lysE encoding lysine efflux permease is reduced, and the ectoine synthesis gene cluster ectABC is expressed. Based on this, the activity of any one or at least two of the following—diaminobutyrate acetyltransferase EctA, pyruvate carboxylase Pyc, or aspartate kinase LysC—is enhanced, and / or the activity of any one or at least two of the following—maloquinone oxidoreductase Mqo or homoserine dehydrogenase Hom—is reduced to further increase ectoine yield.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The invention provides an engineering bacterium for producing spermidine and a preparation method of the engineering bacterium, and relates to the field of genetic engineering. According to the invention, arginine decarboxylase, aspartate kinase, aspartate-semialdehyde dehydrogenase, spermidine efflux protein (MdtI / MdtJ), carboxylaminopropyl agmatine dehydrogenase (CAPADH), carboxylaminopropyl agmatine decarboxylase (CAPADC) and aminopropyl agmatine urea hydrolase (APAUH) are subjected to overexpression in escherichia coli by using a gene engineering technology, and then the escherichia coli is subjected to enzyme deactivation, so that the escherichia coli is obtained. The genetically engineered bacterium capable of producing the spermidine can be obtained by simultaneously knocking out a spermidine transport system (PotBCAD), a spermidine-N-acetyltransferase (spermidine-N-acetyltransferase) and a homoserine dehydrogenase (homoserine dehydrogenase), so that the genetically engineered bacterium capable of producing the spermidine can be obtained. The engineering bacterium greatly reduces the production cost of spermidine, has a wide application prospect, and lays a foundation for green production of spermidine.

The present application relates to the technical field of genetic engineering, and discloses a recombinant Escherichia coli for high-yield O-acetyl-L-homoserine and application thereof. The recombinant Escherichia coli for high-yield O-acetyl-L-homoserine is obtained by the following combination of modification strategies: in Escherichia coli W3110, a gene encoding homoserine O-acetyltransferase is integrated into a gene site encoding L-arginine ABC transporter ATP binding subunit, then a gene encoding phosphoacetyltransferase is knocked out, then a gene encoding transcriptional anti-terminator and mRNA stability regulator is knocked out, then a gene encoding ATP-NAD kinase is integrated into a gene site encoding NADPH-dependent aldehyde reductase, and finally a gene promoter of acetyl-CoA synthetase is replaced by a Ptrc promoter to obtain the recombinant Escherichia coli. The recombinant Escherichia coli is used for fermentation to produce O-acetyl-L-homoserine, and has the advantage of high yield. metx artp patz cspc ppnk yahk acs ​​​​​​​

The invention relates to a method for heterologously producing ganoderic acid, which comprises the following steps: respectively transforming candidate oxidase, candidate reductase and candidate acetyltransferase into corresponding saccharomyces cerevisiae strains for heterologously expressing, and screening the transformed strains through intracellular fermentation or whole-cell catalysis to obtain codon-optimized AfuSDR and CsSDR capable of catalyzing oxidization of hydroxyl of a ganoderma triterpene skeleton C3, the method comprises the following steps of: performing independent expression or combined expression on reductases AKR1C2, AKR1C4 and FusC1 which are optimized by codons and are used for catalyzing C3 keto reduction and acetyltransferase BsAT which is optimized by codons and is used for catalyzing C3 hydroxyl acetylation, so as to realize heterologous biosynthesis of ganoderic acid TR (GA-TR), gibberellic acid Ja (GA-Ja) and ganoderic acid Mf (GA-Mf).

This invention relates to the construction and staining application of recombinant Escherichia coli for synthesizing indoleacetic acid ester. The recombinant Escherichia coli for synthesizing indoleacetic acid ester is obtained by using recombinant Escherichia coli MG1655ΔpheAΔtrpRΔtyrAΔyddGΔarsB::tac70-MaFMOΔldhA::tac70-MaFMOΔyghWX::tac70-tnaAΔpoxB::tac70-cav1 as the initial strain. Then, the endogenous acetylesterase is knocked out, and the endogenous tryptophan hydrolase gene tnaA and the flavin monooxygenase gene maFMO are overexpressed, while simultaneously overexpressing the acetyltransferase gene. The indoleacetic acid ester yield of this invention is as high as 195.3 mg / L. Using indoleacetic acid ester for staining eliminates the need for reducing agents and enzyme solutions, significantly reducing staining costs.

The invention discloses a method for efficiently detecting various microbial limits of tobramycin, belongs to the technical field of microbial detection, and initiates an enzyme-chemical synergistic neutralization system constructed by aminoglycoside-3-acetyltransferase, aminoglycoside-3 '-phosphotransferase, magnesium chloride hexahydrate and a sodium chloride-peptone buffer solution. According to the system, the bacteriostatic activity of tobramycin can be thoroughly eliminated through a direct enzymatic inactivation way, and the limitation that neutralization is not thorough in a traditional method is broken through. Based on the system, the efficient detection method is successfully developed by combining process optimization of adding bacteria and adding a passivating enzyme and a chemical neutralizer into a culture medium. The method has four core advantages of high efficiency, specificity, environmental protection and synergy, can thoroughly eliminate antibacterial interference of tobramycin, and remarkably improves the accuracy and reliability of a microbial limit test result.

The present invention relates to a method of selecting a subject having cancer for treatment comprising: i) determining a KAT6A level of a biological sample of cancer from said subject; ii) selecting a subject for treatment; and iii) administering to the selected subject an amount of one of the following based on the KAT6A level: a) a lysine acetyltransferase 6A (KAT6A) inhibitor; b) a lysine acetyltransferase 6A (KAT6A) inhibitor and a cyclin dependent kinase 4 (CDK4) inhibitor; c) a lysine acetyltransferase 6A (KAT6A) inhibitor and an antiestrogen; and d) a lysine acetyltransferase 6A (KAT6A) inhibitor, a cyclin dependent kinase 4 (CDK4) inhibitor, and an antiestrogen, wherein the KAT6A level is determined as a high KAT6A level.

This invention discloses a genetically engineered bacterium lacking the acetyltransferase gene asp12, its construction method, and its applications. This invention utilizes CRISPR / Cas9 to knock out the asp12 gene encoding acetyltransferase in Aspergillus terreus strain GZU-31-1, constructing the genetically engineered bacterium Δasp12. This invention found that compared to the wild-type Aspergillus terreus strain GZU-31-1, the genetically engineered bacterium Δasp12 exhibits increased accumulation and significantly higher yield of the compound Aspermeroterpene F, which possesses anti-inflammatory and anti-hepatic fibrosis activities. Based on the genetically engineered bacterium Δasp12, this invention also provides a method for preparing the compound Aspermeroterpene F, further improving the yield of the compound by optimizing the fermentation culture medium. This invention is beneficial for the development of anti-inflammatory and anti-hepatic fibrosis drugs.

The invention relates to an Escherichia coli engineering strain for producing 2, 3-hexanediol as well as a construction method and application of the Escherichia coli engineering strain, and the method comprises the following steps: constructing recombinant plasmids pET-FadB-Ter-PhaA for expressing FadB genes of 3-hydroxyacetyl-CoA dehydrogenase and enoyl-CoA hydratase, Ter genes of trans-enoyl-CoA reductase and PhaA genes of acetyl-CoA acetyltransferase; the method comprises the following steps: constructing a recombinant plasmid pRSF-Ilv2C-PduP for expressing an Ilv2C gene of acetohydroxy acid synthetase and a PduP gene of CoA-acylated aldehyde dehydrogenase; and chemically converting the recombinant plasmid pET-FadB-Ter-PhaA and the recombinant plasmid pRSF-Ilv2C-PduP into escherichia coli, so as to obtain the escherichia coli engineering strain for producing the 2, 3-hexanediol. The Escherichia coli engineering strain realizes microbial de novo synthesis of linear beta, gamma-hexanediol for the first time, fills the vacancy in the field of biosynthesis of dihydric alcohol, and expands the application prospect of dihydric alcohol.

The present invention relates to a microorganism containing at least one heterologous gene encoding L-arginine:glycine amidinotransferase (AGAT), at least one heterologous L-threonine 3-dehydrogenase gene (tdh), and at least one heterologous glycine C-acetyltransferase (2-amino-3-oxobutanoate coenzyme A ligase) gene (kbl), as well as a method for the fermentative production of guanidinoacetic acid (GAA) using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

The invention relates to application of cyanobacteria acetyltransferase in increasing the content of astaxanthin in escherichia coli for producing astaxanthin, and also provides a method for increasing the content of astaxanthin in escherichia coli for producing astaxanthin, which comprises the step of introducing a cyanobacteria acetyltransferase gene expression cassette into escherichia coli. The method comprises the following steps: amplifying a target gene cKAT from a genome of blue-green algae, inserting the cKAT into an escherichia coli expression vector by using a recombinant DNA technology, and transforming the constructed expression vector into an escherichia coli BW-ASTA strain to obtain recombinant escherichia coli. Therefore, the content of the astaxanthin in the escherichia coli is increased by about 4 times, and a novel efficient, stable and large-scale microbial synthesis scheme is provided for greatly reducing the production cost of the astaxanthin.

The present invention is related to production of retinyl acetate generated via enzymatic conversion of retinol, said process including the use of modified enzymes with improved activity.

Compounds comprising sulfonyl-purine or sulfonyl-purine analog bonds are described for use as electrophiles in sulfonyl-purine (SuPUR) chemistry. Also described is the use of SuPUR and / or SuPUR chemistry for proteome labeling of reactive amino acid residues and for developing new covalent therapeutic agents that selectively modify select amino acid residues (e.g., tyrosine or lysine residues) in biologically active proteins and peptides, such as amyloid-beta (Aβ)-binding alcohol dehydrogenase (ABAD), guanine nucleotide binding protein alpha stimulating activity polypeptide (GNAS), alpha / beta-hydrolase domain 10 (ABHD10), glutathione S-transferase pi 1 (GSTP1), glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), poly(ADP-ribose) polymerase 2 (PARP2), and acetyl-CoA acetyltransferase 2 (ACAT2) proteins.

The invention relates to the technical field of bioengineering, and discloses a construction method and application of recombinant Escherichia coli engineering bacteria with high yield of ergothioneine, and the method comprises the following steps: by taking Escherichia coli as a chassis, integrating a mycobacterium smegmatis egtABCDE gene cluster at an ldhA site; a repressor protein gene metJ and a cysteine lyase gene yhaM are knocked out, a methionine adenosine transferase gene metK and a serine acetyltransferase gene cysE are overexpressed by using a strong promoter, and mutant metA, thrA, serA and hisG genes for relieving feedback inhibition are introduced, so that metabolic inhibition of methionine, cysteine and histidine pathways is systematically relieved; the invention also establishes a matched fermentation process. According to the invention, endogenous precursor supply and exogenous synthesis pathways are synergistically enhanced, the precursor supply bottleneck is solved, the yield of ergothioneine is increased, and the method is suitable for industrial production.

Disclosed are methods for the fermentative production of a sialylated saccharide and genetically engineered microbial cells for use in said method, wherein the genetically engineered microbial cells comprise (i) a sialic acid biosynthesis pathway comprising a glucosamine-6-phosphate N-acetyltransferase, (ii) a cytidine 5′-monophospho-(CMP)-N-acetylneuraminic acid synthetase; and (iii) a sialyitransferase, for producing sialylated saccharides, as well as the use of said sialylated oligosaccharides for providing nutritional compositions.

This invention discloses a 2,6,10,14-tetramethylpentadecane derivative compound, its preparation method, and its applications. The structure of the compound is shown in formula (I). Compared with natural 2,6,10,14-tetramethylpentadecane, the compound has significantly enhanced binding ability to the malonyl / acetyltransferase functional domain (MAT) of fatty acid synthase (FASN), significantly enhanced ability to inhibit fatty acid synthesis, significantly enhanced therapeutic effect on diseases related to FASN abnormalities, significantly enhanced activation of anti-tumor immunity, and significantly enhanced inhibition of tumor growth. It can be effectively used in the preparation of drugs that inhibit fatty acid synthesis, drugs that treat fatty acid synthesis abnormalities, cancer treatment drugs, and immunotherapy drugs.

The invention relates to production and application of ganoderic acid based on acetyltransferase GlAT, which comprises the following steps: transforming acetyltransferase GlAT in ganoderma lucidum into a corresponding saccharomyces cerevisiae strain for heterologous expression, and implementing heterologous biosynthesis of ganoderic acid TN (GA-TN), ganoderic acid X (GA-X) and ganoderic acid T-Q (GA-T-Q) through fermentation culture, furthermore, GlAT yeast microsomes are prepared to perform in-vitro enzymatic reaction, so that the production of ganoderic acid R (GA-R), ganoderic acid P (GA-P), ganoderic acid Mk (GA-Mk), ganoderic acid T (GA-T) and ganoderic acid T1 (GA-T1) is realized. According to the invention, acetyltransferase participating in ganoderic acid biosynthesis is excavated and identified and is subjected to heterologous expression in saccharomyces cerevisiae, and a plurality of ganoderic acid compounds are obtained through fermentation culture or microsome reaction.

The invention discloses a construction method and application of an engineering bacterium for increasing the yield of alpha-ketoglutaric acid. Wild E.coli.W3110 serves as a chassis strain, lactic dehydrogenase ldhA, pyruvate dehydrogenase poxB and formic acid C-acetyltransferase pflB are knocked out firstly, and the flow direction of pyruvic acid to lactic acid, acetic acid and formic acid is blocked; meanwhile, the promoter PBBaJ23109 is used for replacing a natural promoter of the sucA gene, so that alpha-ketoglutaric acid dehydrogenase is weakened, and the decomposition way of alpha-ketoglutaric acid is weakened; the phosphoenolpyruvate carboxylase ppc is overexpressed, and the flow direction of phosphoenolpyruvate to oxaloacetic acid is enhanced; isocitrate dehydrogenase icd from escherichia coli is overexpressed, so that synthesis of a product is promoted; besides, pyruvate dehydrogenase derived from saccharomyces cerevisiae is introduced and coded by genes PDB1, PDA1 and LAT1, so that an important precursor, namely pyruvic acid, is promoted to flow to acetyl coenzyme A; the engineering strain with high yield of alpha-ketoglutaric acid is finally obtained, the yield of 75.1 g / L can be achieved in a 5L fermentation tank through a fed-batch fermentation method for 40 hours, and the conversion rate is 39.6%.

The invention relates to a method for producing hyaluronic acid through cell-free catalysis, and belongs to the technical field of biological catalysis. According to the invention, a system capable of being applied to cell-free catalytic production of hyaluronic acid is constructed, and genetically engineered bacteria are used for expressing N-acetyl hexosamine 1-kinase, glucosamine-1-phosphate acetyl transferase, glucuronide kinase, GlcA-1-P uridinetransferase, hyaluronic acid synthase, polyphosphate kinase, uridine monophosphate kinase and inorganic pyrophosphatase; according to the present invention, N-acetylglucosamine GlcNAc, glucuronic acid GlcA, ATP and UMP are adopted as substrates to perform catalytic production, UDP and ADP produced during the reaction process are converted into ATP and UTP, such that nucleotide circulation is achieved, raw material consumption is reduced, the final hyaluronic acid yield reaches 1.28 g / L, and an economic and efficient brand new path is provided for hyaluronic acid industrial production.

The invention discloses a construction method and application of escherichia coli genetically engineered bacteria for producing malic acid by synergistically utilizing CO2, and belongs to the technical field of bioengineering. According to the invention, an L-malic acid chassis strain MG1655W (DE3) constructed by a gene editing technology in a laboratory is used as an initial strain, a lactic dehydrogenase encoding gene ldhA and a phosphate acetyltransferase encoding gene pta in escherichia coli are knocked out on the basis, the production paths of lactic acid and formic acid are blocked, and the yield of lactic acid and formic acid is increased. The method comprises the following steps of: firstly, amplifying a phosphoenolpyruvate carboxylase gene ppc and a CO2 transporter gene CA, constructing a recombinant plasmid, introducing the recombinant plasmid pACYCDuet-1-CA-ppc into an expression host MG1655W (DE3) delta ldhA delta pta, and screening to obtain the engineering bacterium MG1655W (DE3) delta ldhA delta pta-CA-ppc by overexpressing the ppc gene and the CA gene and improving the CO2 immobilization and concentration capability of escherichia coli. The obtained engineering bacterium is subjected to cell proliferation under an aerobic condition and malic acid accumulation under an oxygen limiting condition, the final malic acid yield is increased to 140-212%, and the engineering bacterium has important industrial application value.

The disclosure relates to methods of stimulating wound healing comprising administering an effective amount of a modulator of acetyltransferase to the subject. The disclosure also relates to methods of treating or preventing fibrosis, reducing severity of scarring or preventing scarring, inhibiting acetyltransferase, reducing a population of profibrotic fibroblasts, an enhancing SOX10 and / or SOX9 expression in a wound in need thereof comprising administering an EP300 modulator to a subject in need thereof. The disclosure also relates to compositions and pharmaceutical compositions comprising an effective amount of an EP300 modulator.

The invention relates to an Ectoine-producing halophilic bacterium as well as a screening method and application thereof, and belongs to the technical field of microorganisms. According to the Ectoin-producing halophilic bacteria disclosed by the invention, the Ectoin-producing halophilic bacteria are Vreelandelassp., and the Ectoin-producing halophilic bacteria are Ectoin-producing halophilic bacteria. The 16S rRNA of the Ectoin-producing halophilic bacteria has at least 90% of nucleotide sequence consistency with that of SEQ ID NO. 1; the Ectoin halophilic bacteria are used for expressing 2-aminobutyric acid acetyltransferase, 2-aminobutyric acid transaminase and Ectoin synthetase. Through an efficient screening method and deep genome analysis, the novel halophilic strain capable of synthesizing the Ectoine is successfully screened out, and the gene cluster for synthesizing the Ectoine is excavated, so that the production efficiency and yield of the Ectoine can be improved, a microbial resource library is enriched, and the genetic diversity is increased.